zansecimab (LY3127804) / Eli Lilly - LARVOL DELTA

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=62 | Terminated | Sponsor: Eli Lilly and Company | N=105 ➔ 62 | Completed ➔ Terminated

Enrollment change • Monotherapy • Trial termination • Solid Tumor

Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. (PubMed, Clin Med Insights Circ Respir Pulm Med) - P2 | "LY3127804 treatment did not decrease the need for ventilator usage in patients hospitalized with pneumonia and presumed or confirmed COVID-19."

Clinical • Journal • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Septic Shock

A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - P2; N=95; Terminated; Sponsor: Eli Lilly and Company; N=210 ➔ 95; Active, not recruiting ➔ Terminated; Trial terminated for futility.

Clinical • Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=105; Completed; Sponsor: Eli Lilly and Company; Trial completion date: Nov 2020 ➔ May 2020

Clinical • Combination therapy • Monotherapy • Trial completion date • Oncology • Solid Tumor

A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - P2; N=210; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. (PubMed, Br J Cancer) - "LY3127804 monotherapy and its combination with ramucirumab are well tolerated. LY3127804 20 mg/kg was the recommended Phase 2 dose."

Clinical • Combination therapy • Journal • Monotherapy • P1 data • Cervical Cancer • Constipation • Endometrial Cancer • Fatigue • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hypertension • Oncology • Solid Tumor • Squamous Cell Carcinoma

A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - P2; N=200; Recruiting; Sponsor: Eli Lilly and Company; Trial primary completion date: Jun 2020 ➔ Sep 2020

Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

ECU, Vidant begin clinical trial of Covid-19 treatment (WNCT) - "A new clinical trial headed by an East Carolina University ­­­­infectious disease specialist at Vidant Medical Center aims to prevent COVID-19 from causing the type of lung damage....Dr. Paul Cook...began enrolling patients....ECU is one of only eight sites in the United States participating in the trial, which is a collaboration with pharmaceutical company Eli Lilly and Vidant Medical Center....The trial will test whether preventing the effects of Ang2 with this monoclonal antibody can reduce the progression to ARDS or the need for ventilators in COVID-19 patients."

New trial • Infectious Disease • Novel Coronavirus Disease

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=105; Active, not recruiting; Sponsor: Eli Lilly and Company; Trial completion date: May 2020 ➔ Nov 2020

Clinical • Combination therapy • Monotherapy • Trial completion date

A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - P2; N=200; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - P2; N=200; Not yet recruiting; Sponsor: Eli Lilly and Company

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Lilly begins clinical testing of therapies for Covid-19 (Eli Lilly Press Release) - "Lilly is also announcing...that it will advance LY3127804...to Phase 2 testing in pneumonia patients hospitalized with COVID-19 who are at a higher risk of progressing to acute respiratory distress syndrome (ARDS)....This trial will begin later this month at several U.S. centers."

New P2 trial

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=105; Active, not recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Nov 2019 ➔ May 2020

Trial completion date